search
This presentation introduces a Phase II trial exploring adjuvant chemotherapy with immunotherapy for completely resected small cell lung cancer (SCLC). Given the increasing SCLC resections and the lack of advancements in adjuvant therapy, the trial aims to enroll 55 patients, evaluating primary endpoints such as two-year disease-free survival. With approvals from key committees and support from Astrazeneca, the study is expected to commence in 9 to 11 months. Efforts are also underway to establish a collaborative multi-institutional database for historical control. The speaker encourages participation and feedback, providing contact information for further inquiries or recommendations.
